Irinotecan or Oxaliplatin: Which is the First Move for the Mate?

CONCLUSIONS: OXA and IRI are indispensable drugs for mCRC treatment and their selection must be as careful as that of targeted agents. We suggest to take into consideration the interaction between known genomic alterations and OXA and IRI activity to personalize chemotherapy in mCRC patients.
PMID: 33069191 [PubMed - as supplied by publisher]

Source: Current Medicinal Chemistry - October 16, 2020 Category: Chemistry Authors: Morelli C, Formica V, Riondino S, Russo A, Ferroni P, Guadagni F, Roselli M Tags: Curr Med Chem Source Type: research